ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325 - Summary - MDSpire

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

Share

Objective:

To discuss the results from the Pumitamig + DB-1305/BNT325 trial presented at the 2026 ESMO Breast Cancer Congress.

Approach:
  • Trial Overview: The trial investigated the combination of Pumitamig with DB-1305/BNT325 in breast cancer treatment.
Interpretation:

Conclusion:

Original Source(s)

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

  • June 26, 2026

Related Content

Algebraic evaluation of optimization in tumors classification with numerical assessments via a flask–react web interface

Immune niche-associated and niche-regulated plasticity in glioblastoma: state transitions, immune escape, and therapeutic vulnerabilities

A systematic review and meta-analysis of the effects of walking training on cardiorespiratory fitness in cancer patients